Brenton Group
Functional genomics of ovarian cancer
Research summary
We study the genetic changes that happen in ovarian cancer to understand what causes cancer cells to become resistant to treatment. We use medical imaging technology to study how tumours respond to treatment and also to help us study cancers that have spread to other parts of the body. By understanding how drug resistance develops, we hope to improve treatments by tailoring drug regimes according to the genetic ‘signature’ of a patient’s cancer.
Introduction
Our laboratory focuses on discovering improved treatments for epithelial ovarian cancer using laboratory and clinical studies.
Professor James Brenton
Senior Group Leader
Research topics
Related News
See all news-
Institute Group Leaders awarded promotions by the University
26th June 2020
We are delighted to announce that several of our Group Leaders have been promoted in the University of Cambridge Senior Academic Promotions.
Find out more -
Identifying active targets in hard to treat cancers
30th April 2019
Dr Geoff Macintyre and Dr Anna Piskorz have received a Cancer Research UK Innovation Prize to develop a test that could identify active therapeutic targets in hard to treat cancers.
Find out more -
Finding meaningful patterns in complexity of ovarian cancer
13th August 2018
Patterns of genetic mutation in ovarian cancer are helping make sense of the disease and could be used to personalise treatment in future.
Find out more